Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Risedronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 12/20 | 1.00 |
| ▸ | BTN3A1 | O00481 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Risedronic Acid SCHEMBL29362587 | 1.00 | FDPS (1.00) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL4989214 | 0.98 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL2115050 | 0.98 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL3771017 | 0.98 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL3170751 | 0.98 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL2115054 | 0.98 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL22720092 | 0.97 | FDPS (0.94) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL22720090 | 0.97 | FDPS (0.94) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL4643040 | 0.91 | FDPS (0.83) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| SCHEMBL10001488 | 0.91 | FDPS (0.82) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 26182 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146184-A1 | COLORFUL TPU FILM CAPABLE OF BEING HOT-CUT AND PREPARATION METHOD THEREOF | Guangdong Zhongding Technology Development Co., Ltd. (CN) | 2026-05-28 | — | — | US | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122075712-A | Antitumor composition of engineering bacteria and bisphosphonate compounds for expressing hemolysin and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137780-A1 | MATERIALS AND METHODS FOR IMPROVED EXPANSION AND USES OF IMMUNE CELLS | JANSSEN BIOTECH INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137678-A1 | METHODS FOR TREATING OR PREVENTING NEUROENDOCRINE TUMOR FORMATION USING XPO1 INHIBITORS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-05-21 | — | — | US | claimed |
| US-12624057-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2026-05-12 | — | — | US | claimed |
| CN-122005812-A | Combined medicine composition for engineering modification of in vivo target cells | 瑞达信使(杭州)生物技术有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-20260102414-A1 | USE OF DERIVATIVES CONTAINING C-O-P BONDS IN PATIENTS WITH KIDNEY FAILURE | SANIFIT THERAPEUTICS S A (ES) | 2026-04-16 | — | — | US | claimed |
| EP-4725514-A2 | COMPOSITION FOR IMPROVED BONE FRACTURE HEALING | Corthotec Ltd (GB) | 2026-04-15 | — | — | EP | claimed |
| US-5283057-A | Risedronate in oral compositions | THE PROCTER & GAMBLE COMPANY (US) | 1994-02-01 | — | — | US | claimed |
| WO-1994000129-A1 | USE OF PHOSPHONATES FOR THE TREATMENT OF OSTEOPOROSIS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1994-01-06 | — | — | WO | claimed |
| WO-1994000130-A1 | COMPOSITIONS FOR THE TREATMENT OF ARTHRITIS CONTAINING PHOSPHONATES AND NSAIDS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1994-01-06 | — | — | WO | claimed |
| EP-0573604-A1 | METHODS FOR THE TREATMENT OF OSTEOPOROSIS. | NORWICH EATON PHARMA (US) | 1993-12-15 | — | — | EP | claimed |
| EP-0566535-A1 | Compositions comprising methanediphosphonic acids and ion-exchangers | CIBA-GEIGY AG (CH) | 1993-10-20 | — | — | EP | claimed |
| EP-0550385-A1 | Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers | CIBA-GEIGY AG (CH) | 1993-07-07 | — | — | EP | claimed |
| WO-1993011786-A1 | METHODS FOR THE TREATMENT OF OSTEOPOROSIS USING BISPHOSPHONATES AND PARATHYROID HORMONE | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-06-24 | — | — | WO | claimed |
| WO-1993009785-A1 | RISEDRONATE DELAYED-RELEASE COMPOSITIONS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-05-27 | — | — | WO | claimed |
| WO-1992014474-A1 | METHODS FOR THE TREATMENT OF OSTEOPOROSIS | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1992-09-03 | — | — | WO | claimed |
| US-5133972-A | TOPICALLY ADMINISTRABLE PHARMACEUTICAL PREPARATIONS | CIBA-GEIGY CORPORATION (US) | 1992-07-28 | — | — | US | claimed |